Thorough QT studies: Questions and quandaries

Drug Safety

Volumn 33, Issue 1, 2010, Pages 1-14

  Malik, Marek ^a   Garnett, Christine E ^b   Zhang, Joanne ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ZIPRASIDONE;

CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; CONTROL GROUP; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAPHY MONITORING; HEART PROARRHYTHMIA; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; NOTE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STANDARDIZATION; TORSADE DES POINTES;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; GUIDELINES AS TOPIC; HEART RATE; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; PLACEBOS; RISK ASSESSMENT;

EID: 72049116795     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319160-000000000-00000     Document Type: Note

References (55)

1. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Guidance to industry. Fed Regist 2005; 70: 61134-61135
2. ICH topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions and answers (EMEA/ CHMP/ICH/310133/2008) [online]. Available from URL: http://www.emea. europa.eu/pdfs/human/ich/31013308en.pdf [Accessed 2009 Nov 10]
3. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006; 46: 498-507
4. Shah RR. Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance. Drug Saf 2007; 30: 1093-1110
5. Rock EP, Finkle J, Fingert HJ, et al. Assessing proarrhythmic potential of drugs when optimal studies are in-feasible. Am Heart J 2009; 157: 827-836
6. Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fex-ofenadine. Lancet 1999; 353: 980 (Pubitemid 29132610)
7. Renard S, Ostorero M, Yvorra S, et al. Torsades de pointes caused by cetirizine overdose. Arch Mal Coeur Vaiss 2005; 98: 157-161
8. Kent K, Ganetsky M, Cohen J, et al. Non-fatal ventricular dysrhythmias associated with severe salicylate toxicity. Clin Toxicol (Phila) 2008; 46: 297-299
9. Malik M. Facts, fancies, and follies of drug-induced QT/QTc interval shortening. Br J Pharmacol. In press
10. Habib AS, Gan TJ. Pro: the Food and Drug Administration black box warning on droperidol is not justified. Anesth Analg 2008; 106: 1414-1417
11. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electro-cardiographic consequences. JAMA 1993; 269: 1513-1518
12. Routledge PA, Lindquist M, Edwards IR. Spontaneous reporting of suspected adverse reactions to antihistamines: a national and international perspective. Clin Exp Allergy 1999; 29 Suppl. 3: 240-250
13. Pratt CM, Hertz RP, Ellis BE, et al. Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter anti-histamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346-352
14. Hanrahan JP, Choo PW, Carlson W, et al. Terfenadine-associated ventricular arrhythmias and QTc interval prolongation: a retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995; 5: 201-209
15. Walker AM, Szneke P, Weatherby LB, et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-362
16. Moss AJ. The QT interval and torsade de pointes. Drug Saf 1999; 21 Suppl. 1: 5-10
17. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 2003; 12: 31-40
18. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107: 531-536
19. Jimenez JJ, Jimenez JG, Daghistani D, et al. Interaction of chloramphenicol and metabolites with colony stimulating factors: possible role in chloramphenicol-induced bone marrow injury. Am J Med Sci 1990; 300: 350-353
20. Fuller MA, Dostrow V, Gupta S, et al. Practical considerations for carbamazepine use in bipolar disorder. Expert Opin Drug Saf 2006; 5: 501-509
21. Schnyder B, Pichler WJ. Mechanisms of drug-induced allergy. Mayo Clin Proc 2009; 84: 268-272
22. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-495
23. Trepakova ES, Koerner J, Pettit SD, et al. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. HESI Pro-Arrhythmia Committee. J Pharmacol Toxicol Methods 2009; 60: 45-50
24. Zabel M, Acar B, Klingenheben T, et al. Analysis of 12-lead T-wave morphology for risk stratification after myocardial infarction. Circulation 2000; 102: 1252-1257
25. Zabel M, Malik M, Hnatkova K, et al. Analysis of T-wave morphology from the 12-lead electrocardiogram for prediction of long-term prognosis in male US veterans. Circulation 2002; 105: 1066-1070
26. Porthan K, Viitasalo M, Jula A, et al. Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Heart Rhythm 2009; 6: 1202-1208
27. Graff C, Andersen MP, Xue JQ, et al. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome. Drug Saf 2009; 32: 599-611
28. Malik M. Drug-induced changes in the T-wave morphology. Drug Saf 2009; 32: 613-617
29. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008; 48: 13-18
30. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131: 472-480
31. Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52: 311-315
32. Hombach V. Electrocardiography of the failing heart. Cardiol Clin 2006; 24: 413-426
33. Malik M, Andreas JO, Hnatkova K, et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther 2008; 84: 595-603
34. Rautaharju PM, Zhang Z-M. Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electro-physiol 2002; 13: 1211-1218
35. Coker SJ. Drugs for men and women: how important is gender as a risk factor for TdP? Pharmacol Ther 2008; 119: 186-194
36. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: safety testing of drug metabolites, 2008 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm079266.pdf [Accessed 2009 Nov 10]
37. Extramiana F, Maison-Blanche P, Cabanis MJ, et al. Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 2005; 77: 247-258
38. Beasley Jr CM, Mitchell MI, Dmitrienko AA, et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol 2005; 46: 678-687
39. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008; 84:475-480
40. Damle B, Fosser C, Ito K, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol 2009; 49: 291-300
41. Malik M, Hnatkova K, Schmidt A, et al. Electrocardio-graphic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009; 49: 674-683
42. Sechaud R, Dumortier T, Balez S. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther 2009; 47: 321-327
43. Darpo B, Agin M, Kazierad DJ, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006; 46: 598-612
44. Hnatkova K, Gang Y, Batchvarov VN, et al. Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol 2006; 29: 1277-1284
45. FDA background on Zeldox™ (ziprasidone hydrochloride capsules) [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/AC/00/backgrd/ 3619b1b.pdf [Accessed 2009 Nov 10]
46. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial inter-subject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282: H2356-63
47. Malik M. Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. J Electrocardiol 2004; 37 Suppl.: 25-33
48. Salvi V, Karnad DR, Panicker GK, et al. Update on the evaluation of a new drug for effects on cardiac repolariza-tion in humans: issues in early drug development. Br J Pharmacol. In press
49. Zhang J, Machado SG. Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat 2008; 18: 451-467
50. McBride BF, Yang T, Roden DM. Influence of the G2677T/ C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J 2009; 9: 194-201
51. Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, 1997 [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/03/briefing/pubs/cpmp.pdf [Accessed 2009 Nov 10]
52. Hnatkova K, Smetana P, Toman O, et al. Systematic comparisons of electrocardiographic morphology increase the precision of QT interval measurement. Pacing Clin Elec-trophysiol 2009; 32: 119-130
53. Sherazi S, DiSalle M, Daubert JP, et al. Moxifloxacin-induced torsades de pointes. Cardiol J 2008; 15: 71-73
54. Badshah A, Janjua M, Younas F, et al. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. Am J Med Sci 2009; 338: 164-166
55. Zhang X, Silkey M, Schumacher M, et al. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. J Clin Pharmacol 2009; 49: 534-539